Evidence map›Paper›PMID 37754099›Full record

ArticleBiosensors2023

Simultaneous Detection of SARS-CoV-2 Nucleoprotein and Receptor Binding Domain by a Multi-Area Reflectance Spectroscopy Sensor.

Dimitra Tsounidi, Michailia Angelopoulou, Panagiota Petrou, Ioannis Raptis, Sotirios Kakabakos

Open access · goldAbstract read
In one paragraph

Article in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dimitra TsounidiImmunoassays-Immunosensors Lab, Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.ORCID 0000-0002-4979-3457
Michailia AngelopoulouImmunoassays-Immunosensors Lab, Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.
Panagiota PetrouImmunoassays-Immunosensors Lab, Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.
Ioannis RaptisInstitute of Nanoscience and Nanotechnology, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.
Sotirios KakabakosImmunoassays-Immunosensors Lab, Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.ORCID 0000-0002-0043-3119
National Centre of Scientific Research "Demokritos" · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has emphasized the urgent need for point-of-care methods suitable for the rapid and reliable diagnosis of viral infections. To address this demand, we report the rapid, label-free simultaneous determination of two SARS-CoV-2 proteins, namely, the nucleoprotein and the receptor binding domain peptide of S1 protein, by implementing a bioanalytical device based on Multi Area Reflectance Spectroscopy. Simultaneous detection of these two proteins is achieved by using silicon chips with adjacent areas of different silicon dioxide thickness on top, each of which is modified with an antibody specific to either the nucleoprotein or the receptor binding domain of SARS-CoV-2. Both areas were illuminated by a single probe that also collected the reflected light, directing it to a spectrometer. The online conversion of the combined reflection spectra from the two silicon dioxide areas into the respective adlayer thickness enabled real-time monitoring of immunoreactions taking place on the two areas. Several antibodies have been tested to define the pair, providing the higher specific signal following a non-competitive immunoassay format. Biotinylated secondary antibodies and streptavidin were used to enhance the specific signal. Both proteins were detected in less than 12 min, with detection limits of 1.0 ng/mL. The assays demonstrated high repeatability with intra- and inter-assay coefficients of variation lower than 10%. Moreover, the recovery of both proteins from spiked samples prepared in extraction buffer from a commercial self-test kit for SARS-CoV-2 collection from nasopharyngeal swabs ranged from 90.0 to 110%. The short assay duration in combination with the excellent analytical performance and the compact instrument size render the proposed device and assay suitable for point-of-care applications.

Indexed as

COVID-19SARS-CoV-2AntibodiesHumansNucleoproteinsPandemicsSpectrum AnalysisAntibodiesNucleoproteinsmulti-analytereflectance spectroscopySARS-CoV-2 proteins

Identifiers

PMID37754099
PMCPMC10526254
OpenAlexW4386368755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.